0 CHECKOUT

Pheochromocytoma - Pipeline Review, H1 2015

  • ID: 3231010
  • April 2015
  • 64 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AstraZeneca PLC
  • Exelixis, Inc.
  • MediaPharma s.r.l.
  • Pfizer Inc.
  • MORE

Pheochromocytoma - Pipeline Review, H1 2015

Summary

This, ‘Pheochromocytoma - Pipeline Review, H1 2015’, provides an overview of the Pheochromocytoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pheochromocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pheochromocytoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca PLC
  • Exelixis, Inc.
  • MediaPharma s.r.l.
  • Pfizer Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pheochromocytoma Overview
Therapeutics Development
Pipeline Products for Pheochromocytoma - Overview
Pipeline Products for Pheochromocytoma - Comparative Analysis
Pheochromocytoma - Therapeutics under Development by Companies
Pheochromocytoma - Therapeutics under Investigation by Universities/Institutes
Pheochromocytoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Pheochromocytoma - Products under Development by Companies
Pheochromocytoma - Products under Investigation by Universities/Institutes
Pheochromocytoma - Companies Involved in Therapeutics Development
AstraZeneca PLC
Exelixis, Inc.
MediaPharma s.r.l.
Pfizer Inc.
Progenics Pharmaceuticals, Inc.
Pheochromocytoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iobenguane sulfate I 131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MPHE-001B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-43126 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vandetanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pheochromocytoma - Recent Pipeline Updates
Pheochromocytoma - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015
Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma
Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma
Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pheochromocytoma, H1 2015
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Pheochromocytoma - Pipeline by AstraZeneca PLC, H1 2015
Pheochromocytoma - Pipeline by Exelixis, Inc., H1 2015
Pheochromocytoma - Pipeline by MediaPharma s.r.l., H1 2015
Pheochromocytoma - Pipeline by Pfizer Inc., H1 2015
Pheochromocytoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pheochromocytoma Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Pheochromocytoma, H1 2015
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AstraZeneca PLC
Exelixis, Inc.
MediaPharma s.r.l.
Pfizer Inc.
Progenics Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)